Demand for anti-superbug remedies boosts sales outlook at Teva supplier Venus Remedies; Recipharm grabs manufacturing deal from Astimex Pharma;

> Peru's tougher GMP requirements on drugmakers have stymied the approval of new drugs in the country. Article

> Venus Remedies, an India-based supplier of meds for Teva Pharmaceutical Industries ($TEVA), expects 15% growth in sales over the next two years in part because of demand for anti-bacterial drugs against superbugs. Report

> Recipharm sealed a development manufacturing deal with Astimex Pharma. Item

> Under a deal announced Monday, Ark Therapeutics Group will manufacture and provide Lymfactin to Laurantis Pharma. Report